AMENDMENTS TO THE CLAIMS

Please add or amend the claims to read as follows, and cancel without prejudice or disclaimer to resubmission in a divisional or continuation application claims indicated as cancelled:

1. (Amended) A synchronous drug delivery composition comprising:

[a] an erodable, hydrogel-forming polymeric matrix which comprises

a) a ~~hydrogel polymer, wherein said hydrogel polymer is blended with~~ blend which comprises a hydrophilic polymeric cellulose derivative and a hydrophobic polymeric methacrylic acid derivative ~~polymer, so as to form an erodible matrix~~;

b) a drug;

c) an agent which enhances intestinal drug absorption; and

d) an agent which inhibits intestinal drug degradation[;],

wherein erosion of said erodable matrix, permits synchronous release of said drug, said agent which enhances intestinal drug absorption and said agent which inhibits intestinal drug degradation ~~and said hydrogel polymer~~.

2-4 (Cancelled)

5. (previously presented) A pharmaceutical composition comprising the synchronous drug delivery composition of claim 1 and a carrier or diluent.

6. (currently amended) A pharmaceutical composition comprising the synchronous drug delivery composition of claim [2] 28 and a carrier or diluent.

7. (currently amended) A pharmaceutical composition comprising the synchronous drug delivery composition of claim [3] 29 and a carrier or diluent.

8. (cancelled) A pharmaceutical composition comprising the synchronous drug delivery composition of claim 4 and a carrier or diluent.

9. (previously presented) A drug delivery composition according to claim 1, wherein the composition is in the form of a plain matrix tablet.

10. (currently amended) A drug delivery composition according to claim [2] 28, wherein the composition is in the form of a plain matrix tablet.

11. (currently amended) A drug delivery composition according to claim [3] 29, wherein the composition is in the form of a plain matrix tablet.

12-16 (cancelled)

17 (previously presented) A drug delivery composition according to claim 1, wherein the composition is coated with an enterocoating.

18. (currently amended) A drug delivery composition according to claim 28, wherein the composition is coated with an enterocoating.

19. (currently amended) A drug delivery composition according to claim[3] 29, wherein the composition is coated with an enterocoating.

20-22 (cancelled)

23. (currently amended) A method of synchronically ~~release~~ releasing a drug, an agent which inhibits intestinal drug degradation and an agent which enhances intestinal drug absorption, comprising the step of administering the composition of claim [4]1.

24. (previously presented) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 1.

25. (currently amended) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim 28.

26. (currently amended) A method of increasing the bioavailability of a drug, comprising the step of administering the drug delivery composition according to claim [3]29.

27. (cancelled) A method of increasing the bioavailability of a drug comprising the step of administering the drug delivery composition according to claim 4.

28. (New) A drug delivery composition according to claim 1, wherein said cellulose derivative is hydroxypropylmethyl cellulose, methylcellulose, carboxymethyl cellulose or hydroxypropyl cellulose.

29. (New) A drug delivery composition according to claim 1, wherein said methacrylic acid derivative is Eudragit® RL.